Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy

被引:0
|
作者
Yu, Xin [1 ]
Pei, Wei [2 ]
Li, Bei [3 ]
Sun, Shengrong [1 ]
Li, Wenge [1 ,4 ]
Wu, Qi [1 ,2 ]
机构
[1] Wuhan Univ, Dept Breast & Thyroid Surg, Renmin Hosp, Wuhan, Hubei, Peoples R China
[2] Tongji Univ, Canc Ctr, Shanghai Peoples Hosp 10, Sch Med, Shanghai, Peoples R China
[3] Wuhan Univ, Renmin Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China
[4] Shanghai GoBroad Canc Hosp, Dept Oncol, Shanghai, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Exercise; Immunosenescence; Tumor Immunity; Immunotherapy; ACUTE MYELOID-LEUKEMIA; NATURAL-KILLER-CELLS; AGE-RELATED-CHANGES; REGULATORY T-CELLS; HIGHLY-DIFFERENTIATED PHENOTYPE; REDEPLOYS NK-CELLS; RESISTANCE-EXERCISE; DENDRITIC CELLS; IN-VITRO; RECEPTOR EXPRESSION;
D O I
10.7150/ijbs.100948
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aging is associated with a decline in immune function, termed immunosenescence, which compromises host defences and increases susceptibility to infections and cancer. Physical exercise is widely recognized for its myriad health benefits, including the potential to modulate the immune system. This review explores the bidirectional relationship between immunosenescence and physical exercise, focusing on their interplay in shaping antitumor immunity. We summarize the impact of aging on innate and adaptive immune cells, highlighting alterations that contribute to immunosenescence and cancer development. We further delineate the effects of exercise on immune cell function, demonstrating its potential to mitigate immunosenescence and enhance antitumor responses. We also discuss the implications of immunosenescence for the efficacy of immunotherapies, such as immune checkpoint inhibitors and adoptive T cell therapy, and explore the potential benefits of combining exercise with these interventions. Collectively, this review underscores the importance of understanding the complex relationship between immunosenescence, physical exercise, and antitumor immunity, paving the way for the development of innovative strategies to improve cancer outcomes in the aging population.
引用
收藏
页码:910 / 939
页数:30
相关论文
共 50 条
  • [41] Immunosenescence and immunotherapy in older NSCLC patients
    Zhang, Jing
    Zhao, Linlin
    Li, Huzi
    Jia, Yingjie
    Kong, Fanming
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (01) : 9 - 16
  • [42] Principles of tumor immunosurveillance and implications for immunotherapy
    Adrian F Ochsenbein
    Cancer Gene Therapy, 2002, 9 : 1043 - 1055
  • [43] Principles of tumor immunosurveillance and implications for immunotherapy
    Ochsenbein, AF
    CANCER GENE THERAPY, 2002, 9 (12) : 1043 - 1055
  • [44] TUMOR AND HOST HETEROGENEITY - IMPLICATIONS FOR IMMUNOTHERAPY
    KILLION, JJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 1 - 1
  • [45] Immunosenescence: deficits in adaptive immunity in the elderly
    Hakim, F. T.
    Gress, R. E.
    TISSUE ANTIGENS, 2007, 70 (03): : 179 - 189
  • [46] Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy
    Thomas, Susan N.
    Rohner, Nathan A.
    Edwards, Erin E.
    ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 18, 2016, 18 : 207 - 233
  • [47] Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
    Jiang, Hong
    Hegde, Samarth
    DeNardo, David G.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (08) : 1037 - 1048
  • [48] Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy
    Gu, Xu
    Liu, Yu'e
    Dai, Xiangpeng
    Yang, Yong-Guang
    Zhang, Xiaoling
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
    Hong Jiang
    Samarth Hegde
    David G. DeNardo
    Cancer Immunology, Immunotherapy, 2017, 66 : 1037 - 1048
  • [50] EFFECT OF IMMUNOTHERAPY, CHEMOTHERAPY, AND SURGERY ON TUMOR IMMUNITY IN MICE
    TANAKA, T
    SASAKI, N
    GANN, 1974, 65 (05): : 395 - 402